Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP) - Hsiao, Edward C.; Di Rocco, Maja; Cali, Amanda; Zasloff, Michael; Al Mukaddam, Mona; Pignolo, Robert J.; Grunwald, Zvi; Netelenbos, Coen; Keen, Richard; Baujat, Genevieve; Brown, Matthew A.; Cho, Tae‐Joon; et al. (British journal of clinical pharmacology, 2019)
Keywords: Bone Remodeling - drug effects; Clinical Trials as Topic - methods; Consensus; Fibrodysplasia ossificans progressiva (FOP); Humans; Myositis Ossificans - diagnosis; Myositis Ossificans - drug therapy; Myositis Ossificans - physiopathology; Ossification, Heterotopic - diagnosis; Ossification, Heterotopic - drug therapy; Ossification, Heterotopic - physiopathology; Patient Safety; Patient Selection; rare disease clinical trials; Research Design; Review‐themed Issue; Stakeholder Participation; rare disease clinical trials; patient safety; Fibrodysplasia ossificans progressiva (FOP)